Many pharmacists probably already have seen prescriptions for Glucophage (metformin hydrochloride), a new drug developed for patients with noninsulin-dependent diabetes mellitus, or NIDDM. The oral antihyperglycemic, from Bristol-Myers Squibb Co., Princeton, N.J., won Food and Drug Administration approval in the spring and is indicated for some people with NIDDM, either as an adjunct to diet therapy or in conjunction with a sulfonylurea, such as chlorpropamide or glyburide. While Glucophage ...
REGISTER TO VIEW THIS ARTICLE - Register for a Free Account
Why Register for FREE?
Registering for content on Supermarket News will give you INSTANT access to invaluable articles and media content that industry professionals rely on. You will have access to our special reports, feature articles, and industry analysis. It’s FREE, easy and quick. What are you waiting for! In addition you will also receive a complimentary copy of SN's salary survey sent to you by email.
Attention Paid Print Subscribers: While you have already been granted free access to SN we ask that you register now. We promise it will only take a few minutes! Or visit your profile and add your print magazine account number and zip code.